For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
Trump administration decision highlights disastrous Part D redesign
The Trump administration recently announced the end of a demonstration project that was pulled together by the Biden administration as the Inflation Reduction…
Blog
Fauci’s lasting legacy will be the damage he did to science and government
Anthony Fauci isn’t faring well in the court of public opinion. His recently divulged “diary” and subsequent July 29 appearance before the Senate Homeland…
Blog
State Directed Payments redistribute money across states and supercharged growth
Differences in states’ use of SDPs cause an interstate redistribution of taxes as well. Because states are setting different levels of SDPs, spending varies…
Search Posts
Op-Eds
Vaccine Disease Protections Outweigh Side Effects
It’s quite unusual for me to write follow-up columns, but I had such an overwhelming response to my recent column…
Op-Eds
Give Nestlé a Break
Generally, the European left has no love for big American financial firms. But some Swiss shareholder activists have embraced the U.S.’s largest proxy-advisory service in…
Washington Post
Painkiller Decision suggest shift in FDA’s risk-benefit equation
Op-Eds
Nation Descends into Mercury Madness
Mercury is all over the news these days, which is appropriate for an element named after the messenger of the gods. At some Maryland high…
Citation
Americans told fish tales about mercury hazards in fish consumption
Products
The Drug Reimportation Controversy
As policy battles go, the drug reimportation debate is an unusual one. On its face, the federal ban on reimporting pharmaceuticals appears to violate the…